Colossal Bioscience’s attempt to de-extinct the dire wolf is a dangerously deceptive publicity stunt
By David Coltman, Carson Mitchell, Liam Alastair Wayde Carter, and Tommy Galfano,
The Conversation
| 05. 12. 2025
Colossal Biosciences, a Texas-based biotech company, made headlines this April after falsely claiming to resurrect the extinct dire wolf. The company presents this as a breakthrough for conservation biology. However, our team of conservation geneticists at the Western University — along with many other academics views it as a dangerous deception.
Colossal’s so-called dire wolf is not a resurrected species. It’s a genetically modified grey wolf. Its creation is a publicity stunt designed to generate profit, with serious consequences.
Jenga approach to conservation
Conservation aims to safeguard ecosystems by preserving the networks of interaction between animals and their environment. Human activity has caused widespread habitat loss, driving extinction rates to levels estimated to be about 1,000 times higher than the natural background rate. We are living through a biodiversity crisis, and conservation remains our only real defence against further declines.
Colossal proposes de-extinction to combat this crisis, using a Jenga-block metaphor to explain their approach. The ecosystem is a Jenga tower, with each species representing a block — and losing a species weakens the structure, pushing it...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...